Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The companies restructured AMRN's $46.5 million in debt obligations to ELN. AMRN may pay $30 million in cash no later than Dec. 31, and
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury